Search - tctmd.com

Displaying 21 - 40 of 99

Sort: Relevancy | Date

News Daily News

Top General Cardiology and CVD Prevention News of 2023

Yael L. Maxwell

January 03, 2024

News Daily News

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

Caitlin E. Cox

December 06, 2023

News Opinion CV Team Dispatch

December 2023 Dispatch for the CV Team

L.A. McKeown

December 01, 2023

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Caitlin E. Cox

November 07, 2023

News Daily News

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

Yael L. Maxwell

October 19, 2023

News Conference News EACTS 2023

SWEDEHEART Hints at Mortality Benefit With Statins After SAVR

Michael O'Riordan

October 05, 2023

News Daily News

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Michael O'Riordan

September 29, 2023

News Daily News

Inactivity Pandemic Poised to Undo CVD Prevention Advances

Michael O'Riordan

April 11, 2023

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

News Conference News ACC 2023

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

Todd Neale

March 10, 2023

News Conference News ACC 2023

Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk

Shelley Wood

March 08, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2023

Caitlin E. Cox

February 01, 2023

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

News Daily News

Mediterranean Diet Bests Low Fat for Secondary Prevention: CORDIOPREV

Michael O'Riordan

May 09, 2022

News Daily News

Icosapent Ethyl Cost-effective Compared With Standard Care: REDUCE-IT

Yael L. Maxwell

February 17, 2022

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

Todd Neale

November 15, 2021

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Shelley Wood

November 08, 2021

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Daily News

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

Michael O'Riordan

January 28, 2021

Advertisement

Top General Cardiology and CVD Prevention News of 2023

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

December 2023 Dispatch for the CV Team

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

SWEDEHEART Hints at Mortality Benefit With Statins After SAVR

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Inactivity Pandemic Poised to Undo CVD Prevention Advances

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

TCTMD’s Top 10 Most Popular Stories for January 2023

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Mediterranean Diet Bests Low Fat for Secondary Prevention: CORDIOPREV

Icosapent Ethyl Cost-effective Compared With Standard Care: REDUCE-IT

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Roughly 80% of ESC Guideline Writers Have Financial COIs

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content